Navigation Links
Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay
Date:10/2/2008

tatements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover and develop novel diagnostics and therapeutic tools, which is unproven and may never lead to marketable products or services; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop its candidate tools, products and services, all of which are in early stages of development; Rosetta's ability to obtain regulatory clearances or approvals that may be required for its products and services; the ability to obtain coverage and adequate payment from health insurers for the products and services comprising Rosetta's technology; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-look
'/>"/>
SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
2. Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement With Johns Hopkins University
3. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Societys Annual Meeting
4. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
5. Hopkins Report: Focusing on Family Planning Lessens HIV Impact
6. Queens University Chooses Xceeds Ziplex(R) System for Translational Research
7. deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer
8. The University of Nottingham in the British Midlands Announces Breakthrough in Parkinsons Disease Research
9. Boston University and The Center for Human Genetics, Inc. Announce Change in Testing Services
10. First U.S. Patient to Receive New Heart-Assist Device Doing Well After Surgery at University of Michigan
11. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... WASHINGTON , Jan. 15, 2014 AARP Foundation today ... support older adults suffering from the severe cold weather that ... are committed to helping those in need; so to support ... dollar-for-dollar contributions up to $250,000, which could mean up to ...
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation (the "Company") ... has received commitments from institutional investors to purchase an ... stock in an at-the-market registered direct offering, led by ... entered into definitive purchase agreements with these investors pursuant ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Radial Strength, FlexibilityHOUSTON, March 18 IDEV Technologies ... and marketing of minimally invasive technologies, announced today ... has approved an investigational device exemption (IDE) for ... a novel stent platform designed for the treatment ...
... March 18 ULURU Inc. (NYSE Alternext: ULU) ... diabetic foot ulcers, and data on the use of ... presented at the annual DFCon Global Meeting in Los ... presented on posters that will be on display during ...
Cached Medicine Technology:U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies' SUPERA Peripheral Stent 2ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009 2ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009 3
(Date:4/17/2014)... 2014-- Colic affects about one in five infants in ... visits during the first several months after birth. Research ... showing promise; however, the April 1, 2014 issue of ... reported on a study, "Probiotics and Infant Colic," concluding ... for infant colic did not reduce crying ...
(Date:4/17/2014)... YORK April 17, 2014 EcoHealth Alliance, a ... health issues, published a comprehensive review today examining the ... Marburg virus. The review calls for improved global surveillance ... as the recent outbreak of Ebola in West Africa ... the countries of Guinea and Liberia. According to ...
(Date:4/17/2014)... by Cesar A. Arias, M.D., Ph.D., at The University ... identified a new superbug that caused a bloodstream infection ... April 17 issue of The New England Journal ... of a class of highly-resistant bacteria known as methicillin-resistant ... major cause of hospital and community-associated infections. The superbug ...
(Date:4/17/2014)... WINSTON-SALEM, N.C. April 17, 2014 Meaningful ... from advanced cancer of the abdomen when treated ... HIPEC, according to a first-of-its-size analysis by physicians ... Forest Baptist has the largest reported, single-center experience ... Edward A. Levine, M.D., and analysis of 20 ...
(Date:4/17/2014)... study has found that India,s shocking rates of suicide ... who are clinging to tiny smallholdings less than ... such as cotton and coffee, that are highly susceptible ... range of previous case studies that point to a ... the ,liberalisation, of the nation,s economy during the 90s. ...
Breaking Medicine News(10 mins):Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:New MRSA superbug emerges in Brazil 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3
... Pressure-Lowering Device to be Available at 1,440 Stores ... April 28 InterCure Ltd., a medical,device company ... (TASE: INCR),today announced that its RESPeRATE(R) hypertension treatment ... into,full-scale retail distribution within the United Kingdom this ...
... motherhood more than doubled in six years among teenage ... published in the May issue of Diabetes Care. ... at gestational diabetes (diabetes that develops during pregnancy, then ... the largest and most diverse study to examine pre-pregnancy ...
... they take, changes in biological clock put many at risk ... Many older adults don,t get enough sleep, which can increase ... disease and diabetes, says the American Academy of Sleep Medicine. ... disturbed sleep and waking up tired every day aren,t a ...
... osteoporosis, , , SATURDAY, April 26 (HealthDay News) -- While ... harmless enough, recent research suggests that those tasty drinks ... enough evidence that high consumption of soda and carbonated ... children, and that,s a real concern and people should ...
... Irvine, Calif., April 25, 2008 -- Advance directives, or ... life-sustaining treatment preferences often change without people being aware ... by UC Irvine researchers Peter Ditto and Elizabeth Loftus. ... in the discrepancy between an individual,s true preferences for ...
... PRINCETON, N.J., April 25 Medarex, Inc.,(Nasdaq: ... BMY ) today announced,that, after meeting with the ... delay the Biologics License Application (BLA) submission for,ipilimumab, ... The FDA has requested additional overall survival (OS),data ...
Cached Medicine News:Health News:InterCure Secures Nationwide Distribution Agreement With Lloyds Pharmacy Group 2Health News:InterCure Secures Nationwide Distribution Agreement With Lloyds Pharmacy Group 3Health News:InterCure Secures Nationwide Distribution Agreement With Lloyds Pharmacy Group 4Health News:Kaiser Permanente study finds diabetes doubling before motherhood 2Health News:Kaiser Permanente study finds diabetes doubling before motherhood 3Health News:Elderly More Likely to Battle Sleep Disorders 2Health News:Cola May Be Bad to the Bones 2Health News:Cola May Be Bad to the Bones 3Health News:Study shows false memories complicate end-of-life treatment decisions 2Health News:Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab 2Health News:Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab 3Health News:Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab 4Health News:Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab 5
Used for the retrieval of stones, stents, or other objects in the urinary tract under direct vision. Retrieval Forceps are designed for use through rigid or flexible endoscopes. Supplied sterile in p...
Used for the retrieval of stones, stents, or other objects in the urinary tract under direct vision. Retrieval Forceps are designed for use through rigid or flexible endoscopes. Supplied sterile in p...
Fulgurating Electrode, 2 F...
ACMI S-Series Cystourethroscope Systems: Precision instruments designed for superior optical recognition, accurate control, and exceptional durability during steam autoclave sterilization....
Medicine Products: